TERN Stock Price, Terns Pharmaceuticals, . Quote, Chart

Market Summary

USD5.90-0.24

Market Closed

-3.91%

TERN Stock Price

View Fullscreen

TERN RSI Chart

TERN Valuation

Market Cap

381.6M

Price/Earnings (Trailing)

-4.19

Price/Sales (Trailing)

29.58

EV/EBITDA

-3.5

Price/Free Cashflow

-5.03

TERN Price/Sales (Trailing)

TERN Profitability

EBT Margin

-703.66%

Return on Equity

-38.47%

Return on Assets

-36.9%

Free Cashflow Yield

-19.89%

TERN Fundamentals

TERN Revenue

Revenue (TTM)

12.9M

Rev. Growth (Yr)

18.16%

Rev. Growth (Qtr)

8.32%

TERN Earnings

Earnings (TTM)

-91.1M

Earnings Growth (Yr)

-3.93%

Earnings Growth (Qtr)

-6.44%

Breaking Down TERN Revenue

Last 7 days

6.1%

Last 30 days

30.0%

Last 90 days

-24.9%

Trailing 12 Months

-41.2%

How does TERN drawdown profile look like?

TERN Financial Health

Current Ratio

27.85

TERN Investor Care

Shares Dilution (1Y)

14.11%

Diluted EPS (TTM)

-1.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.7M	0	0	12.9M
2022	228.0K	387.0K	837.0K	2.1M
2021	0	118.0K	117.0K	170.0K
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Terns Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	vivo opportunity, llc	sold	-25,723	6.2	-4,149	-
Apr 03, 2024	vivo opportunity, llc	sold	-643,994	6.2	-103,870	-
Apr 03, 2024	vivo opportunity, llc	sold	-186,291	6.2	-30,047	-
Apr 02, 2024	vivo opportunity, llc	sold	-146,859	6.65	-22,084	-
Apr 02, 2024	vivo opportunity, llc	sold	-20,282	6.65	-3,050	-
Apr 02, 2024	vivo opportunity, llc	sold	-507,701	6.65	-76,346	-
Apr 01, 2024	vivo opportunity, llc	sold	-275,483	6.99	-39,411	-
Apr 01, 2024	vivo opportunity, llc	sold	-38,102	6.99	-5,451	-
Apr 01, 2024	vivo opportunity, llc	sold	-952,422	6.99	-136,255	-
Jan 23, 2024	quirk erin	acquired	-	-	75,000	president, head of r&d

Which funds bought or sold TERN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-46.52	-493,426	580,540	0.06%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-13.2	-29,449	210,642	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-26.07	-105,703	312,597	-%
May 15, 2024	ADAR1 Capital Management, LLC	reduced	-61.56	-51,615	32,800	0.01%
May 15, 2024	Exome Asset Management LLC	new	-	1,494,510	1,494,510	1.28%
May 15, 2024	Aquatic Capital Management LLC	new	-	9,184	9,184	-%
May 15, 2024	Stone House Investment Management, LLC	new	-	6,560	6,560	-%
May 15, 2024	Squarepoint Ops LLC	new	-	468,128	468,128	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-34.77	-130,048	251,668	-%
May 15, 2024	Eversept Partners, LP	new	-	1,856,700	1,856,700	0.12%

Are Funds Buying or Selling TERN?

Are funds buying TERN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TERN

No. of Funds

Unveiling Terns Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 07, 2024	point72 asset management, l.p.	6.3%	3,881,341	SC 13G
Feb 14, 2024	deep track capital, lp	9.87%	6,100,000	SC 13G/A
Feb 14, 2024	fairmount funds management llc	9.9%	6,632,015	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	7.3%	4,497,117	SC 13G/A
Feb 13, 2024	lav biosciences fund v, l.p.	1.5%	919,523	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.5%	5,837,126	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.5%	3,408,978	SC 13G
Jan 25, 2024	integrated core strategies (us) llc	5.6%	3,434,178	SC 13G
Oct 13, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Terns Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 02, 2024	3	Insider Trading
May 02, 2024	4	Insider Trading
Apr 29, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Terns Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Terns Pharmaceuticals, Inc. News

Latest updates

Terns Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q2	2020Q1
Revenue	8.3%	3,182,000	2,937,500	2,693,000	1,328,000	499,000	214,000	69,000	55,000	49,000	55,000	11,000	2,000	50,000
Costs and Expenses	5.8%	25,446,000	24,058,000	24,157,000	16,828,000	17,292,000	14,084,000	13,825,000	14,878,000	11,868,000	10,818,000	13,296,000	10,097,000	9,423,000
S&GA Expenses	-100.0%	-	6,599,000	7,101,000	6,170,000	5,131,000	5,422,000	5,689,000	5,416,000	4,715,000	4,857,000	4,561,000	2,486,000	2,179,000
EBITDA Margin	-0.9%	-7.01	-6.95	-14.21	-28.20	-69.05	-136	-217	-289	-380	-374	-	-	-
Income Taxes	98.0%	97,000	49,000	60,000	318,000	13,000	6,000	21,000	435,000	20,000	14,000	39,000	-	-
Earnings Before Taxes	-6.2%	-22,276,000	-20,970,000	-21,468,000	-15,504,000	-16,807,000	-13,924,000	-13,752,000	-13,813,000	-11,815,000	-10,724,000	-13,298,000	-9,845,000	-9,206,000
EBT Margin	-0.9%	-7.04	-6.97	-14.30	-28.43	-69.65	-137	-219	-292	-385	-379	-	-	-
Net Income	-6.4%	-22,373,000	-21,019,000	-21,528,000	-15,822,000	-16,820,000	-13,930,000	-13,773,000	-14,248,000	-11,835,000	-10,738,000	-13,337,000	-9,688,000	-9,001,000
Net Income Margin	-0.9%	-7.06	-6.99	-14.39	-28.60	-70.22	-138	-221	-295	-391	-385	-	-	-
Free Cashflow	-17.9%	-22,827,000	-19,360,000	-14,382,000	-11,245,000	-13,428,000	-11,169,000	-13,542,000	-10,869,000	-8,156,000	-8,802,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-8.1%	247	269	272	290	301	287	193	145	157	168	180	188	199	92.00
Current Assets	-8.1%	246	267	270	288	300	285	191	143	154	167	179	187	198	91.00
Cash Equivalents	-18.6%	65.00	80.00	38.00	81.00	184	143	63.00	17.00	44.00	48.00	65.00	68.00	99.00	75.00
Net PPE	-11.7%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-23.6%	10.00	13.00	13.00	16.00	14.00	10.00	9.00	8.00	8.00	8.00	8.00	7.00	9.00	24.00
Current Liabilities	-26.1%	9.00	12.00	12.00	14.00	12.00	8.00	7.00	6.00	6.00	7.00	7.00	6.00	8.00	23.00
Shareholder's Equity	-7.3%	237	255	258	274	288	277	184	137	149	160	172	181	190	-
Retained Earnings	-6.7%	-355	-332	-311	-281	-263	-242	-226	-209	-195	-182	-167	-155	-145	-131
Additional Paid-In Capital	0.7%	592	588	571	557	552	520	412	348	345	343	340	337	335	15.00
Shares Outstanding	0.1%	65.00	65.00	62.00	61.00	57.00	54.00	30.00	25.00	25.00	25.00	22.00	20.00	-	-
Float	-	-	-	-	409	-	-	-	47.00	-	-	-	225	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-18.0%	-22,798	-19,316	-20,699	-12,993	-14,382	-11,211	-13,436	-11,162	-13,300	-10,669	-8,082	-8,760	-14,316	-7,387	-6,313	-8,822	-7,287
Share Based Compensation	22.7%	4,028	3,282	14,083	4,233	3,938	2,687	2,686	2,651	2,744	2,550	1,855	1,909	1,832	786	513	190	202
Cashflow From Investing	-83.1%	7,997	47,232	-22,313	-90,837	27,931	-14,546	-1,240	-15,974	9,488	-6,421	4,443	-20,902	-96,816	-47.00	-5.00	-102	6,847
Cashflow From Financing	-100.0%	-	13,862	20.00	489	27,580	105,970	61,001	124	-	16.00	797	-1,589	135,169	68,640	32.00	16,876	-33.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TERN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 18,587	$ 17,056
General and administrative	6,859	7,101
Total operating expenses	25,446	24,157
Loss from operations	(25,446)	(24,157)
Other income:
Interest income	3,182	2,693
Other expense, net	(12)	(4)
Total other income, net	3,170	2,689
Loss before income taxes	(22,276)	(21,468)
Income tax expense	(97)	(60)
Net loss	$ (22,373)	$ (21,528)
Net loss per share, basic	$ (0.3)	$ (0.31)
Net loss per share, diluted	$ (0.3)	$ (0.31)
Weighted average common stock outstanding, basic	74,399,378	69,778,420
Weighted average common stock outstanding, diluted	74,399,378	69,778,420
Other comprehensive loss:
Net loss	$ (22,373)	$ (21,528)
Unrealized (loss) gain on available-for-sale securities, net of tax	(293)	418
Foreign exchange translation adjustment, net of tax	(9)	(12)
Comprehensive loss	$ (22,675)	$ (21,122)

TERN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets(Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 65,099	$ 79,926
Marketable securities	175,555	183,514
Prepaid expenses and other current assets	5,241	3,992
Total current assets	245,895	267,432
Property and equipment, net	447	506
Operating lease assets	369	523
Other assets	55	56
Total assets	246,766	268,517
Current liabilities:
Accounts payable	1,701	2,515
Accrued expenses and other current liabilities	6,700	8,826
Current portion of operating lease liabilities	427	603
Total current liabilities	8,828	11,944
Taxes payable, non-current	1,218	1,206
Total liabilities	10,046	13,150
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value, 150,000,000 shares authorized at March 30, 2024 and December 31, 2023; 64,651,693 and 64,576,719 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	592,036	588,008
Accumulated other comprehensive loss	(321)	(19)
Accumulated deficit	(355,001)	(332,628)
Total stockholders' equity	236,720	255,367
Total liabilities and stockholders' equity	$ 246,766	$ 268,517

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

WEBSITE	ternspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	46

Terns Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Terns Pharmaceuticals, Inc.? What does TERN stand for in stocks?

TERN is the stock ticker symbol of Terns Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Terns Pharmaceuticals, Inc. (TERN)?

As of Fri May 17 2024, market cap of Terns Pharmaceuticals, Inc. is 381.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TERN stock?

You can check TERN's fair value in chart for subscribers.

What is the fair value of TERN stock?

You can check TERN's fair value in chart for subscribers. The fair value of Terns Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Terns Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TERN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Terns Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether TERN is over valued or under valued. Whether Terns Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Terns Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TERN.

What is Terns Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TERN's PE ratio (Price to Earnings) is -4.19 and Price to Sales (PS) ratio is 29.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TERN PE ratio will change depending on the future growth rate expectations of investors.